{
    "clinical_study": {
        "@rank": "126135", 
        "acronym": "GRIIF", 
        "arm_group": {
            "arm_group_label": "Allogeneic transplantation of intrahepatic islet", 
            "arm_group_type": "Experimental", 
            "description": "Allogeneic transplantation of intrahepatic islet number required for insulin independence of obtaining, with a threshold dose of 9,000 IEQ/kg body weight of the recipient and a maximum sequence number of 3 infusions. The patient will receive after transplantation immunosuppressive therapy with Thymoglobulin for induction, Prograf and Cellcept, both of which are given throughout the duration of the study"
        }, 
        "brief_summary": {
            "textblock": "It is a multicentre, sequential, phase II clinical trial, aiming at evaluating the\n      allogeneic islet transplantation for the treatment of type 1 diabetes.\n\n      19 patients with type 1 diabetes will be included and ideally distributed evenly: patients\n      with unstable diabetes without renal insufficiency (AI group for \"islet alone\" by the\n      international customary determination) and patients with a functioning kidney transplant\n      (IAK group for \"islet after kidney\"). The main endpoint will be defined by the restoration\n      of normal glycemic control without insulin at 6 months after graft."
        }, 
        "brief_title": "Allogeneic Islet Transplantation for the Treatment of Type 1 Diabetes", 
        "completion_date": {
            "#text": "January 2021", 
            "@type": "Anticipated"
        }, 
        "condition": "Patients With Type 1 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with type 1 diabetes\n\n          -  18 <Age <55 years\n\n          -  Plasma C-peptide <0.2 ng/ml basal and stimulated glucagon\n\n          -  Evolution of diabetes for more than 5 years\n\n          -  Regular patient follow-up (> or equal to 2 visits per year from the same\n             diabetologist)\n\n          -  Patient who received the information and have given their consent in writing\n\n          -  Absence of HIV, hepatitis B and hepatitis C, HTLV-1-2\n\n          -  ABO compatibility with the donor\n\n          -  Cross match negative\n\n          -  Anti-HLA antibodies (class I and / or class II) detected by lymphocytotoxicity <20%\n\n          -  PCR negative for the BK virus in the blood (so as not to amplify the BK virus\n             replication with the ATG).\n\n          -  Accepting patients effective contraception during the study period\n\n        For patients in group IA\n\n          -  Glomerular filtration rate estimated by the MDRD> 50 ml/min/1.73m2\n\n          -  No perception of hypoglycaemia (less than 0.54 mg/dl glucose) at least one value\n             documented in the two years preceding and/or\n\n          -  Occurrence of at least one severe hypoglycemic episode (with a third required) and\n             unexplained in the two years before and/or at least two episodes of ketoacidosis per\n             year\n\n          -  Average HbA1c> 8.5% over two years, despite intensified treatment (basal pattern,\n             bolus)\n\n             \u2022 For patients in the IAK\n\n          -  functional renal graft for at least 1 year\n\n          -  glomerular filtration rate> 50 ml/min/1.73 m2\n\n          -  proteinuria <0.5 g/day\n\n          -  Absence of acute rejection in renal previous 6 months\n\n        Exclusion Criteria:\n\n          -  BMI > 28\n\n          -  Need insulin > 1 U/kg per day\n\n          -  Pregnancy, lactation\n\n          -  Intention of childbearing for the two sexes\n\n          -  Psychiatric Disorders\n\n          -  Inability to communicate or cooperate with the investigator\n\n          -  Lack of therapeutic compliance, including HbA1C > 12%\n\n          -  Chronic liver disease\n\n          -  Progressive heart disease  myocardial infarction within 6 months prior to inclusion,\n             unbalanced CHD)\n\n          -  Proliferative retinopathy unstabilized\n\n          -  History of cancer, whatever the date, except for basal or squamous cell skin cancers\n             over 1 year.\n\n          -  Systemic infection\n\n          -  Chronic high risk of requiring corticosteroids\n\n          -  Need for long-term corticosteroid, outside that specified in renal transplantation,\n             the patients will be weaned before transplantation\n\n          -  Anticoagulant vitamin K or antiplatelet treatments\n\n          -  Disorders of hemostasis TP <60 % TCA > 1.5 times the control\n\n          -  Anti-HLA antibodies ( class I and/or class II ) detected by lymphocytotoxicity > 20%\n\n          -  Platelets < 100 giga/L and/or neutrophils <1.5 giga/L\n\n          -  Chronic intoxication by alcohol, tobacco, or other substance (abstinence > 6 months\n             required)\n\n          -  Active infection by hepatitis B, hepatitis C and HIV, HTLV-1-HTLV2\n\n          -  Ascites"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "19", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01974674", 
            "org_study_id": "P030415"
        }, 
        "intervention": {
            "arm_group_label": "Allogeneic transplantation of intrahepatic islet", 
            "intervention_name": "Allogeneic transplantation of intrahepatic islet", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "diabetes", 
            "transplantation"
        ], 
        "lastchanged_date": "April 22, 2014", 
        "location": {
            "contact": {
                "email": "pierre.cattan@sls.aphp.fr", 
                "last_name": "Pierre CATTAN, MD PhD", 
                "phone": "33 1 42494786"
            }, 
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "state": "Ile de France", 
                    "zip": "75010"
                }, 
                "name": "Saint Louis hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Allogeneic Islet Transplantation for the Treatment of Type 1 Diabetes", 
        "overall_contact": {
            "email": "pierre.cattan@sls.aphp.fr", 
            "last_name": "Pierre CATTAN, MD PhD", 
            "phone": "33 1 42494786"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "the restoration of normal glycemic control without insulin therapy will be evaluated by measuring\n- A fasting glucose (> 8 hours) less than 1.25 g/L and a 2 hours glucose after oral intake of 75g of glucose, less than  2 g/L in a patient without insulin for at least 15 consecutive days during the the first 6 months from day 0.", 
            "measure": "restoration of normal glycemic control without insulin", 
            "safety_issue": "No", 
            "time_frame": "6 months after graft"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01974674"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Restoration of normal glycemic control without insulin for a year", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "HbA1c <6.5%, with lower insulin doses by 30%", 
                "measure": "Obtaining an improvement in glycemic control", 
                "safety_issue": "No", 
                "time_frame": "within 2 years after inclusion"
            }, 
            {
                "description": "The remission of diabetes is defined by the normality of blood glucose or insulin without lHbA1c.\nThe normality of blood glucose is defined below 1.20 g/L and postprandial fasting glycemia less than 1.60 g/L in the book self-monitoring (including 6/7 blood glucoses during the previous 3 days evaluation visit).\nNormal HbA1c is defined as less than 6.5%.", 
                "measure": "Obtaining a remission of diabetes", 
                "safety_issue": "No", 
                "time_frame": "within 2 years after inclusion"
            }, 
            {
                "measure": "Improved metabolic profile determined by the OGTT and hyperglycemic clamp", 
                "safety_issue": "No", 
                "time_frame": "within 2 years after inclusion"
            }, 
            {
                "description": "defined on blood glucose and / or glucose holter", 
                "measure": "Decreased glycemic variability", 
                "safety_issue": "No", 
                "time_frame": "within 2 years after inclusion"
            }, 
            {
                "measure": "Reduction of oxidative stress assessed by the urinary excretion of 24 hours of 8-iso-PGF2 rates.", 
                "safety_issue": "No", 
                "time_frame": "within 2 years after inclusion"
            }, 
            {
                "measure": "Decrease in the frequency, severity or poor perception of hypoglycaemia defined Hypo score", 
                "safety_issue": "Yes", 
                "time_frame": "within the 2 years after inclusion"
            }, 
            {
                "description": "defined by questionnaires DQOL and SF-36", 
                "measure": "quality of life", 
                "safety_issue": "Yes", 
                "time_frame": "within 2 years after inclusion"
            }, 
            {
                "description": "defined by the rate of C-peptide", 
                "measure": "term graft survival", 
                "safety_issue": "Yes", 
                "time_frame": "within 2 years of inclusion"
            }, 
            {
                "description": "based on beta-score", 
                "measure": "beta-cell function", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "number of IEQ/kg of recipient required to reduce the daily insulin dose of 1 unit", 
                "measure": "potential of each infusion of islets", 
                "safety_issue": "No", 
                "time_frame": "within 2 years after inclusion"
            }, 
            {
                "measure": "degenerative complications of diabetes", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}